What did @my.journey.with.marc actually say?
Mark's core argument is simple: the leftover liquid in a Mounjaro pen after four doses is not a bonus fifth dose. He says it's "overfilled" intentionally to ensure dose accuracy, that it's "not measured" and "not sterile after a month," and that extracting it with a syringe risks underdosing, overdosing, or injecting bacteria. He's describing a real TikTok trend where users try to squeeze out residual tirzepatide from a spent pen as a cost-saving measure.
He's careful to frame this as personal opinion and not medical advice, which is the right instinct. He also redirects viewers appropriately: if your current dose feels insufficient, talk to a prescriber. That's a reasonable and responsible message. The question is whether his specific technical claims about why the golden dose is risky actually hold up to scrutiny.
Does the science back this up?
Mostly, yes. Eli Lilly's own prescribing information for Mounjaro confirms that autoinjector pens are designed with an overfill to account for dead space and delivery mechanics. The drug that remains after the labeled doses is not formulated as an additional measured dose. That's not a conspiracy; it's standard pharmaceutical engineering across most prefilled injectors.
The sterility concern is also legitimate. Once a pen cap is removed and the needle tip is used, contamination risk accumulates with each injection event. A pen used over four weeks, then punctured again with a third-party syringe to aspirate residual fluid, is no longer in the sterile conditions Eli Lilly tested. There's no published clinical study specifically on golden dose extraction because no responsible ethics board would greenlight one. What we do have is general pharmaceutical guidance from the FDA on autoinjector integrity and contamination risk. The American Society of Health-System Pharmacists has published repeatedly on the dangers of dose manipulation in prefilled devices.
What did they get wrong (or right)?
Mark gets the headline right. The golden dose is not a validated, safe practice. But his explanation of why deserves some nuance.
The claim that residual liquid is "not sterile after a month" is directionally correct but slightly imprecise. The sterility issue isn't purely about time. It's about whether the pen's needle and reservoir have been compromised during use. Tirzepatide itself, stored correctly in a refrigerator, remains stable for the duration labeled in the prescribing information. The risk is microbial contamination from syringe insertion into an already-used device, not automatic degradation on a 30-day clock.
His overdose concern is also worth clarifying. The residual volume in most autoinjector pens is typically small. A 2019 analysis by Hasson et al. in the Journal of Diabetes Science and Technology found residual volumes in prefilled insulin pens ranged from 5 to 30 microliters, far below a pharmacologically significant dose. Tirzepatide pens aren't identical, but the general principle holds. Overdose from residual volume alone is unlikely. The real risks are contamination, inaccurate dosing, and using inappropriate extraction equipment. Mark gets the risk right; he just picks the least supported mechanism.
What should you actually know?
The golden dose trend exists because tirzepatide is expensive and supply has been inconsistent. That's a real financial pressure on real patients, and dismissing the behavior without acknowledging that context misses the point. Mark actually does acknowledge it: "I get it. These pens are expensive." That's the right framing.
Here's what the evidence actually supports. First, pharmaceutical manufacturers deliberately include overfill in prefilled devices. This is confirmed in regulatory submissions and is not secret. Second, that overfill is not a precision dose. Third, extracting residual drug with a syringe introduces contamination risk and removes the dose-accuracy guarantees the device was designed to provide. Fourth, if cost is the driver, the conversation should be with a prescriber about dose optimization, patient assistance programs, or whether a compounded tirzepatide option through a legitimate licensed pharmacy is appropriate given the individual's clinical situation. Compounded tirzepatide is not the same as brand-name Mounjaro, and that distinction matters clinically and legally.
Mark's redirect to healthcare providers is exactly right. If your dose feels insufficient, that is a clinical conversation, not a DIY extraction project.